Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yusang Zhang

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Iscience|April 25, 2025
NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligandShuqing Tang, Yusang Zhang, Peiyun Wang, et al.
BMC Medicine|June 29, 2026
Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8<sup>+</sup> T-cell activationShuqing Tang, Mengting Han, Peiyun Wang, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Iscience|April 25, 2025
NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligandShuqing Tang, Yusang Zhang, Peiyun Wang, et al.
BMC Medicine|June 29, 2026
Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8<sup>+</sup> T-cell activationShuqing Tang, Mengting Han, Peiyun Wang, et al.
Pageof 1